LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

LLY

818.58

+0.92%↑

JNJ

156.9

+0.22%↑

ABBV

190.58

-0.85%↓

NVO

79.74

-1.64%↓

UNH

313.25

-1.52%↓

Search

Akebia Therapeutics Inc

Cerrado

SectorSalud

3.54 -2.75

Resumen

Variación precio

24h

Actual

Mínimo

3.51

Máximo

3.56

Métricas clave

By Trading Economics

Ingresos

29M

6.1M

Ventas

11M

57M

BPA

0.025

Margen de beneficio

10.66

Empleados

181

EBITDA

20M

14M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+89.61% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

395M

1B

Apertura anterior

6.29

Cierre anterior

3.54

Noticias sobre sentimiento de mercado

By Acuity

28%

72%

82 / 380 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Akebia Therapeutics Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

13 jun 2025, 22:33 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefonica Ecuador for $380 Million

13 jun 2025, 23:50 UTC

Adquisiciones, fusiones, absorciones

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- 2nd Update

13 jun 2025, 23:20 UTC

Adquisiciones, fusiones, absorciones

Trump and Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- Update

13 jun 2025, 23:09 UTC

Adquisiciones, fusiones, absorciones

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal -- WSJ

13 jun 2025, 23:03 UTC

Adquisiciones, fusiones, absorciones

Trump, Nippon Steel Reach National-Security Agreement on U.S. Steel Deal --WSJ

13 jun 2025, 22:18 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefonica Ecuador for $380M

13 jun 2025, 22:04 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Better Data Facilitate Investments In Oil Patch -- Market Talk

13 jun 2025, 21:42 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- 2nd Update

13 jun 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

Bunge: Outside Date Extended to July 3

13 jun 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

Bunge: Subject to Satisfaction of Remaining Conditions, Bunge and Sellers Expect to Complete Transaction July 2

13 jun 2025, 21:34 UTC

Adquisiciones, fusiones, absorciones

Bunge Gets Mexico Approval for Viterra Deal

13 jun 2025, 21:32 UTC

Adquisiciones, fusiones, absorciones

Bunge Gets China Approval for Viterra Deal

13 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

13 jun 2025, 20:45 UTC

Adquisiciones, fusiones, absorciones

23andMe: TTAM Makes Binding Commitments for Additional Consumer Protections and Privacy Safeguards

13 jun 2025, 20:34 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- Update

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Nonprofit Controlled By 23andMe Co-Founder Anne Wojcicki Would Buy the DNA-Testing Company for $305 Million -- WSJ

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Anne Wojcicki Wins Bidding for 23andMe -- WSJ

13 jun 2025, 20:14 UTC

Adquisiciones, fusiones, absorciones

Regeneron Walks Away From 23andMe Acquisition After Wojcicki's Higher Bid -- WSJ

13 jun 2025, 19:30 UTC

Charlas de Mercado

U.S. Natural Gas Futures Post Moderate Gains -- Market Talk

13 jun 2025, 19:12 UTC

Charlas de Mercado

Oil Futures Jump As Israel Strikes Iranian Targets -- Market Talk

13 jun 2025, 19:04 UTC

Charlas de Mercado

Canada Military Spending Hike to Lift Long-Term Yields -- Market Talk

13 jun 2025, 18:54 UTC

Charlas de Mercado

Correction to Gold Settles Market Talk

13 jun 2025, 18:01 UTC

Charlas de Mercado

Gold Settles at Record High -- Market Talk

13 jun 2025, 17:40 UTC

Charlas de Mercado

U.S. Oil Rig Count Falls By 3 to 439 -- Market Talk

13 jun 2025, 17:21 UTC

Charlas de Mercado

Dollar Index, Commodities Rise -- Market Talk

13 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

Advent Proposal Values Spectris at GBP37.63 Per Share, Company Said Monday -- WSJ

13 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

KKR Is Preparing a Bid for High-Tech Instrument Maker Spectris, Sources Say -- WSJ

13 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

Private-Equity Firm Is Vying With Advent for the U.K. Company, Sources Say -- WSJ

13 jun 2025, 17:02 UTC

Adquisiciones, fusiones, absorciones

KKR Making Competing Bid for Equipment Maker Spectris -- WSJ

13 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

Comparación entre iguales

Cambio de precio

Akebia Therapeutics Inc Esperado

Precio Objetivo

By TipRanks

89.61% repunte

Estimación a 12 meses

Media 6.75 USD  89.61%

Máximo 8 USD

Mínimo 6 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Akebia Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

2.345 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bullish Evidence

Sentimiento

By Acuity

82 / 380 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Akebia Therapeutics Inc

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.